Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su-Chun Cheng

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinomaDavid F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinomaDavid F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Pageof 8